Human Galectin-1 and Its Inhibitors: Privileged Target for Cancer and HIV

(E-pub Ahead of Print)

Author(s): Narella Sridhar Goud, P. S. Lakshmi Soukya, Mahammad Ghouse, Daipule Komal, Ravi Alvala, Mallika Alvala*.

Journal Name: Mini-Reviews in Medicinal Chemistry

Submit Manuscript
Submit Proposal


Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, implicate in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape. Gal-1 is considered as a biomarker in diagnosis, prognosis and treatment condition. The overexpression of Gal-1 is well established and seen in many types of cancer progressions like osteosarcoma, breast, lung, prostate and melanoma etc. Gal-1 greatly accelerates the binding kinetics of HIV-1 to susceptible cells, leading to faster viral entry and a more robust viral replication by specific binding of CD4 cells. Hence, the Gal-1 is considered as promising molecular target for the development of new therapeutic drugs for Cancer and HIV. Present review laid emphasis on structural insights and functional role of Gal-1 in the disease, current Gal-1 inhibitors and future prospects in design of specific Gal-1 inhibitors.

Keywords: Galectin 1, cancer, HIV, Gal-1 inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389557519666190304120821
Price: $95

Article Metrics

PDF: 2